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The staggerer mice carry a deletion in the ROR gene
and have a prolonged humoral response, overproduce
inflammatory cytokines, and are immunodeficient. Fur-
thermore, the staggerer mice display lowered plasma
apoA-I/-II, decreased plasma high density lipoprotein
cholesterol and triglycerides, and develop hypo--li-
poproteinemia and atherosclerosis. However, relatively
little is known about ROR in the context of target tis-
sues, target genes, and lipid homeostasis. For example,
ROR is abundantly expressed in skeletal muscle, a ma-
jor mass peripheral tissue that accounts for 40% of
total body weight and 50% of energy expenditure. This
lean tissue is a primary site of glucose disposal and fatty
acid oxidation. Consequently, muscle has a significant
role in insulin sensitivity, obesity, and the blood-lipid
profile. In particular, the role of ROR in skeletal mus-
cle metabolism has not been investigated, and the con-
tribution of skeletal muscle to the ROR/ phenotype
has not been resolved. We utilize ectopic dominant neg-
ative ROR expression in skeletal muscle cells to under-
stand the regulatory role of RORs in this major mass
peripheral tissue. Exogenous dominant negative ROR
expression in skeletal muscle cells represses the endog-
enous levels of ROR and - mRNAs and ROR-depend-
ent gene expression. Moreover, we observed attenuated
expression of many genes involved in lipid homeostasis.
Furthermore, we show that the muscle carnitine palmi-
toyltransferase-1 and caveolin-3 promoters are directly
regulated by ROR and coactivated by p300 and PGC-1.
This study implicates RORs in the control of lipid home-
ostasis in skeletal muscle. In conclusion, we speculate
that ROR agonists would increase fatty acid catabolism
in muscle and suggest selective activators of ROR may
have therapeutic utility in the treatment of obesity and
atherosclerosis.
Members of the nuclear hormone receptor (NR)1 superfamily
bind specific DNA elements and function as transcriptional
regulators (1, 2). This group includes the “orphan NRs,” which
have no known ligands in the “classical sense.” The orphan
receptor, ROR/RZR (retinoic acid receptor-related orphan re-
ceptor), is closely related to Rev-erbA, RVR/Rev-erb/BD73,
and the Drosophila orphan receptor, E75A, particularly in the
DNA-binding domain and the putative ligand-binding domain.
ROR, Rev-erbA, and RVR bind as monomers to an asymmetric
(A/T)6RGGTCA motif. ROR functions as a constitutive trans-
activator of gene expression, and in contrast, Rev-erbA and
RVR do not activate transcription, mediate transcriptional re-
pression, and can repress constitutive trans-activation from
this motif by ROR (3–9).
Three ROR/RZR genes have been identified; ROR encodes
four ROR isoforms 1, 2, 3, and RZR, which are alterna-
tively spliced products of the ROR gene and are predomi-
nantly expressed in blood, brain, skeletal muscle, and fat cells
(8, 10). ROR/RZR is expressed specifically in the brain (11),
and ROR is found at high levels in skeletal muscle (12–14).
Genetic studies have implicated ROR in the regulation of
lipid homeostasis. For example, analysis of ROR function has
been assisted by a natural mutation in an obese mouse strain
called staggerer (sg/sg). The mutation produces a dominant
negative ROR that results in a functional knockout pheno-
type. In accordance with the wide expression pattern of ROR,
staggerer mice show symptoms of ataxia and cerebellar dys-
function, susceptibility to atherosclerosis and hypo--lipopro-
teinemia, vascular dysfunction, muscular irregularities, osteo-
porosis, and severe immune abnormalities. In the context of
lipid homeostasis, the staggerer mice exhibit an aberrant blood
lipid profile with lower circulating plasma levels of HDL-C,
apolipoprotein (apo) CIII, and plasma triglycerides. Decreases
in specific lipoprotein compartments, namely apoAI, the major
constituent of HDL, and apoAII, leads to a pronounced hypo-
-lipoproteinemia (16). Accordingly, it has been shown that
ROR regulates the expression of apoAI and apoCIII in cell
culture (16, 17). Susceptibility to atherosclerosis in this animal
model is linked to a complex phenotype that includes aberrant
vascular physiology, lipid profiles, and hypersensitive inflam-
matory responses.
Studies examining motor capabilities and coordination in
staggerer mice have shown a reduction of muscular strength in
these mice (18). Furthermore, the studies of Lau et al. (19)
demonstrated that ROR potentiates skeletal muscle myogen-
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esis, and the comments in a review by Jarvis et al. (20) suggest
that staggerer mice have skeletal muscle irregularities.
The association between ROR, lipid homeostasis, and skel-
etal muscle is not surprising. ROR is abundantly expressed in
skeletal muscle, which is one of the most metabolically de-
manding tissues that relies heavily on fatty acids as an energy
source and accounts for 75% of glucose disposal. Moreover, this
suggests that muscle has an important role in obesity, which is
primarily controlled by increased food intake or decreased en-
ergy expenditure. However, the fundamental role of ROR in
skeletal muscle cholesterol, lipid, glucose, and energy homeo-
stasis has not been examined. Moreover, the contribution of
skeletal muscle, a major mass tissue, to the ROR knockout
phenotype has not been resolved.
The involvement of ROR in the progression of atheroscle-
rosis identifies ROR as a therapeutic target in the treatment
of cardiovascular disease. In addition, skeletal muscle is rap-
idly emerging as a critical target tissue in the battle against
obesity, type II diabetes, dyslipidemia, syndrome X, and ath-
erosclerosis. NRs in skeletal muscle, for example liver X recep-
tor (LXR), peroxisome proliferator-activated receptors (PPAR)
, /, and , have been shown to be involved in enhancing
insulin-stimulated glucose disposal rate, decreasing triglycer-
ides and increasing lipid catabolism, cholesterol efflux, and
plasma HDL-C levels (21–23). Hence, orphan NRs that regu-
late lipid and glucose metabolism, cholesterol homeostasis, en-
ergy expenditure, and thermogenesis in skeletal muscle have
enormous pharmacological utility for the treatment of dyslipi-
demia and syndrome X.
We hypothesize that ROR regulates lipid, glucose, and en-
ergy homeostasis in this major mass lean tissue. This hypoth-
esis was addressed by examining the effect of ectopically ex-
pressing the staggerer form of ROR in muscle cells and by
investigating the subsequent effect on gene expression involved
in lipid metabolism. Our investigation reveals that ROR has a
central role in the regulation of lipid metabolism in muscle
cells. Moreover, we suggest that the atherogenic and dyslipi-
demic phenotype of the staggerer mouse is related to aberrant
ROR function in skeletal muscle.
MATERIALS AND METHODS
Cell Culture—Mouse myogenic C2C12 cells were cultured in growth
medium (DMEM supplemented with 10% Serum Supreme (BioWhit-
taker, Edward Keller Pty. Ltd., Hallam, Victoria, Australia)) in 6% CO2.
Myoblasts were differentiated into post-mitotic multinucleated myo-
tubes by 1–5 days of serum withdrawal (i.e. cultured in DMEM supple-
mented with 2% horse serum). Cells were harvested at indicated time
points, usually 120 h (5 days) after the mitogen withdrawal, unless
indicated differently. African green monkey kidney COS-1 cells were
grown in DMEM supplemented with 10% heat-inactivated fetal calf
serum.
Transient Transfections—Each well of a 24-well plate of COS-1 cells
(60% confluence) was transfected with a total of 0.6–0.8 g of DNA
per well by using the liposome-mediated transfection procedure as
described previously (19). Cells were transfected using an N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate and
Metafectene (Biontex Laboratories GmbH, Munich, Germany) liposome
mixture in 1 HBS (HEPES-buffered saline (42 mM HEPES, 275 mM
NaCl, 10 mM KCl, 0.4 mM Na2HPO4, 11 mM dextrose (pH 7.1)). The
DNA/N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium meth-
ylsulfate/Metafectene mixture was added to the cells in 0.5–0.6 ml of
DMEM supplemented with 5% charcoal-stripped fetal calf serum.
16–24 h later, the culture medium was changed, and the cells were
subsequently harvested for the assay of luciferase activity 24–48 h
after the transfection period as described previously. Fold activation is
expressed relative to LUC activity obtained after cotransfection of the
reporter and pSG5 vector only, arbitrarily set at 1. The mean fold
activation values and standard deviations were derived from a mini-
mum of two independent experiments composed of six replicates. CAT
assays were described previously (19). Transient transfections were
performed at least twice in sextuplicate.
C2C12 Stable Transfection—Myogenic C2C12 cells, cultured in
growth medium, were cotransfected with pSG5-RORDE (and pCMV-
NEO at a 20:1 ration of expression vector/NEO vector) by the liposome-
mediated procedure in duplicate. The cells were then grown for another
24 h to allow cell recovery and neomycin resistance expression before
G418 selection. After 10–14 days selection with 450 g/ml G418 (In-
vitrogen) in culture medium, the two independent polyclonal pools
(100 colonies per pool) of stable transfectants were cultured and
maintained on 200 g/ml G418 medium.
RNA Extraction—Total RNA was extracted from C2C12 using TRI-
Reagent (Sigma), according to manufacturer’s protocol. RNA for quan-
titative real time (Q-RT)-PCR, was further purified by using RNeasy
(Qiagen, Clifton Hill, Victoria, Australia), according to manufacturer’s
instructions. This was followed by DNase treatment with DNA-free
(Ambion, Austin, TX.)
Q-RT-PCR—RNA was normalized using UV spectrophotometry and
agarose gel electrophoresis. Complementary DNA was synthesized
from 7 g of total RNA by Superscript3, according to the manufacturer’s
instruction (Invitrogen). Target cDNA levels were analyzed by Q-RT-
PCR in 25-l reactions containing either 1 SYBR green (ABI, War-
rington, UK) or Taqman PCR master mix (I, Branchburg, NJ), 200
nM each forward and reverse primers or Assay on Demand Taqman
primers (ABI, Foster City, CA) and cDNA (0.6% of the starting 7 g of
RNA) by using an ABI Prism 7000 Sequence Detector system. PCR was
conducted over 45 cycles of 95 °C for 15 s and 60 °C for a 1-min two-step
thermal cycling preceded by an initial 95 °C for 10 min for activation of
Amplitaq Gold DNA polymerase.
Primers—The Mus musculus primer sequences (forward and reverse,
respectively) used are as follows: ABCA1, GCTCTCAGGTGGGAT-
GCAG and GGCTCGTCCAGAATGACAAC; 18 S, GATCCATTGGAGG-
GCAAGTCT and CCAAGATCCAACTACGAGCTTTTT; A8/G1, CTGA-
GGGATCTGGGTCTGA and CCTGATGCCACTTCCATGA; ACS4, GG-
TTTGGTAACAGATGCCTTCAA and CCCATACATTCGCTCAATGT-
CTT; ADRP, CCCTGGTTCTAAGAAGCTGCTTT and GGCCAGATGA-
CCCCTTTTG; AdipoR1, ACGTTGGAGAGTCATCCCGTAT and CTCT-
GTGTGGATGCGGAAGAT; AdipoR2, TCCCAGGAAGATGAAGGGT-
TTAT and TTCCATTCGTTCGATAGCATGA; apoE, GCTGTTGGTCA-
CATTGCTGA and TGCCACTCGAGCTGATCTG; -actin, GCTCTGG-
CTCCTAGCACCAT and CCACCGATCCACACAGAGTAC; CD36, GG-
CCAAGCTATTGCGACAT and CAGATCCGAACACAGCGTAGA; CA-
V-3, CTGCCCCCAGGACTATCAAC and TTCCAGATCCGTGTGCTC-
TTC; CPT1b, ATCATGTATCGCCGCAAACT and CCATCTGGTAGGA-
GCACATGG; FABP3, CCCCTCAGCTCAGCACCAT and CAGAAAAA-
TCCCAACCCAAGAAT; FAS, CGGAAACTTCAGGAAATGTCC and
TCAGAGACGTGTCACTCCTGG; GAPDH, GTGTCCGTCGTGGAT-
CTGA and CCTGCTTCACCACCTTCTTG; Glut4n ATGGCTGTCGCT-
GGTTTCTC and ACCCATACGATCCGCAACAT; Glut5, CTTGCCTTT-
ACCGGGTTGAC and CATCTGGTCTTGCAGCAACTCT; MyoG, CCT-
TAAAGCAGAGAGCATCC and GGAATTCGAGGCATAATATGA; LPL,
CCAATGGAGGCACTTTCCA and TGGTCCACGTCTCCGAGTC;
mROR, CAATGCCACCTACTCCTGTCC and GCCAGGCATTTCTG-
CAGC; PGC-1, CGATGTGTCGCCTTCTTGCT and CGAGAGCGCATC-
CTTTGG; Rev-erb, CCACACCGCTGGGAGAGT and GCCCTGGCGTA-
GACCATTC; RVR, GGAAACACTCATCCGTGCACTA and ATC-
GAAGATCTGGCAACTTTAGAA; SCD-1, TGTACGGGATCATACTG-
GTTCC and CCCGGCTGTGATGCC; SCD-2, ACTGTGACTCAAGT-
TCAACTCTTGAAA and TGCCCACAAATTGAGGATAGC; and
SREBP-1c, CGTCTGCACGCCCTAGG and CTGGAGCATGTCT-
TCAAATGTG; TNNI1, GCCTATGCGCACACCTTTG and CGGGTAC-
CATAAGCCCACACT; TNNI2, AAATGTTCGAGTCTGAGTCCTA-
ACTG and GCCAAGTACTCCCAGACTGGAT; UCP-2, GTTCC-
TCTGTCTCGTCTTGC and GGCCTTGAAACCAACCA; and UCP-3,
TGACCTGCGCCCAGC and CCCAGGCGTATCATGGCT.
Human ROR-specific primers contain 3 of 5 base difference at the 3
end of the reverse primer relative to mouse primers. hROR: CAATG-
CCACCTACTCCTGTCC and CTACGGCAAGGCATTTCTGTAAT.
GAPDH and 18 S were used for normalization between samples for
quantitation. Assay on Demand primers were used for Taqman real
time PCR (ABI, Foster City CA) mhROR (Mm00443103_m1); ROR
(Mm00441139_m1); FABP4 (Mm00445880_m1); GAPDH
(Mm99999915_g1); 18 S rRNA (Hs99999901_s1).
Plasmids—Human pSG5-ROR1 has been previously described (19).
ROREx5-tk-LUC containing five copies of RORE (TATATCAAGGT-
CAT) was cloned into pTKLuc as described by Medvedev et al. (24).
mPCP-2x4-tk-LUC containing four copies of mouse Pcp-2 RORE (GT-
TATAGTAACTGGGTCAGGGGACT) was cloned into pTKLuc as de-
scribed by Matsui (25). The inserted sequences in the TKLuc clones
were confirmed by big dye terminator version 3.1 cycle sequencing
ROR Regulates Lipid Homeostasis in Skeletal Muscle 36829
 at UQ Library on October 11, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
(ABI, Foster City, CA). The CPT-1 promoter (	1025/	12) was kindly
provided by D. P. Kelly (26); cDNA-GRIP1/SRC2 and cDNA-p300
have been described previously (27). CDNA4-PGC-1 was kindly pro-
vided by Spiegelman and co-workers (28). 2.6-kb mouse caveolin-3
promoter was isolated from a BAC clone 23N20 (Incyte Genetics) and
cloned into a HindIII site of pGL3basic. Deletion constructs of the
Cav-3 promoter were obtained using native restriction sites or by
PCR with Pfu DNA polymerase. The DNA sequences of these con-
structs were confirmed by cycle sequencing (Applied Biosystems).
GLUT4-pGL2 was obtained by PCR cloning of a mouse skeletal mus-
cle genomic DNA into pGL2basic. The DNA sequence containing a
2.2-kb sequence upstream of the transcription start site was con-
firmed by cycle sequencing. pGEX-ROR1 was described previously
(19); GAL4-ROR constructs were cloned in-frame into the multiple
cloning site of vector pGAL0 and confirmed by dideoxy sequencing
(Amersham Biosciences).
Site-directed Mutagenesis—pGL3-Cav3Luc (	2595/35) was mu-
tated by QuickChange PCR site-directed mutagenesis (Stratagene) ac-
cording to the manufacturer’s instructions. 125 ng of oligonucleotides
containing GG to TT mutation and its complementary strand (see se-
quences below) were added to a PCR containing 50 ng of pGL3-Cav3Luc
(	2595/35), dNTP, 1 Pfu buffer, and Pfu or Pfu ultra. After re-
striction digestion with DpnI, the reaction was transformed into DH5.
The colonies were screened, and the sequence was confirmed by cycle
sequencing after DNA extraction. The oligonucleotides to mutate the
mouse caveolin-3 promoter are as follows: Cav-3 mut2 oligos, GAGGA-
TACAATCTCGTGTCAAATACTCACCCGCCCCG and CGGGGCGGG-
TGAGTATTTGACACGAGATTGTATCCTC; and the Cav-3 mut6 oligos,
CATGCGGCTCCCAGTGAAAGACTTCCTCCTCTCGAG and CTCG-
AGAGGAGGAAGTCTTTCACTGGGAGCCGCATG.
Oligonucleotide Probes and EMSA—Double-stranded oligonucleotide
probes used in EMSA and for cold competition are as follows: RORE,
5-TCGACTCGTATATCAAGGTCAAGCGTG-3 (8); mouse pcp-2, 5-G-
TTATAGTAACTGGGTCAGGGGACTC-3 (25); Cav-3 m1, CTGAGAA-
CTACGTCATGGCCTTTG; Cav-3 m2, CTCGTGTCACCTACTCAC-
CCG; Cav-3 m3, CTGCTCCAAGGCACAGGAGAGCAGAGC; Cav-3 m4,
AGCAGAGCAAGGTCTTTGTCCCTTTGGTGTC; Cav-3 m5, CATGGA-
CAAGGTAAAGGGGAGGCTTATAACTG; and Cav-3 m6, CCAGT-
GACCGACTTCCTCCTCT.
GST-ROR1 was prepared as previously described (19, 52). 100 ng of
double-stranded oligonucleotide was radiolabeled with 5 l of
[-32P]ATP and T4 polynucleotide kinase and purified by 6%
TBE-PAGE.
EMSAs were carried out as described previously with modifications
(52, 55). 0.4 g of GST-ROR1 protein in Dignam buffer C (0.1 M NaCl,
20 mM HEPES (pH 7.9), 2 mM EDTA, 1 mM dithiothreitol, and 1
complete protease inhibitor (Roche Applied Science)) was incubated
with 1 g of poly(dI-dC)(dI-dC), 4 g of bovine serum albumin, 1
complete protease inhibitor (Roche Applied Science), 300 cps of gel-
purified 32P double-stranded radioactive probe end-labeled by T4
polynucleotide kinase, 12% glycerol, 0.6 mM dithiothreitol, and 1
binding buffer (53) on ice for 30 min before gel separation. Cold com-
petition studies were carried out by coincubation with 100–300 ng of
double-stranded unlabeled probe.
RESULTS
ROR and - mRNA Expression Are Induced during Myo-
genic Differentiation—ROR and - mRNAs are expressed in
skeletal muscle tissue. To elucidate the functional role of ROR
in skeletal muscle, we initially investigated the expression of
ROR mRNA relative to the 18 S rRNA in the mouse C2C12
myoblast cell line. This skeletal muscle cell line has proven to
be a reliable system to study skeletal muscle lipid homeostasis
in cell culture (21–23).
Proliferating C2C12 myoblasts can be induced to biochemi-
cally and morphologically differentiate into post-mitotic
multinucleated myotubes by serum withdrawal in culture over
a 48–96-h period. This transition from a non-muscle phenotype
to a contractile phenotype is associated with the repression of
non-muscle proteins and the activation/expression of a struc-
turally diverse group of genes responsible for contraction and
to cope with the extreme metabolic demands on this organ
(Fig. 1A).
By using the GenBankTM sequences of ROR and -, we
designed specific primers for the amplification of mouse ROR
by quantitative real time PCR from total RNA isolated from
proliferating and differentiated C2C12 cells (Fig. 1A). Total
poly(A) RNA was isolated from proliferating myoblasts
(PMB), confluent myoblasts (CMB), and post-mitotic myotubes
after 2 and 5 days (MT2 and MT5) of serum withdrawal and
examined by real time PCR and “Northern blot” analysis.
We observed that ROR and - are expressed in proliferating
myoblasts; however, these transcripts are induced 2.5–4-fold,
relative to 18 S rRNA and GAPDH mRNA (data not shown), as
the cells exit the cell cycle and fuse to form differentiated
multinucleated myotubes that have acquired a muscle-specific
phenotype (Fig. 1, B and D). ROR is seen transcribed as a
double band (Fig. 1C) in C2C12 as described in differentiated
P19 cells (3). Concomitant with this increase in ROR encoding
mRNAs was the striking induction of myogenin mRNA (Fig.
1E), which encodes the hierarchical bHLH regulator, and re-
pression of the cytoskeletal non-muscle -actin mRNA (Fig.
1F), which confirmed that these cells had terminally differen-
tiated. Moreover, we observed the induction of the slow and fast
isoforms of the contractile protein, troponin I (Fig. 1, G and H).
These data demonstrated that the ROR and - mRNA tran-
scripts were expressed in C2C12 cells, and expression is in-
creased upon myotube formation.
Induction of ROR and - mRNAs correlated with the re-
pression of the mRNAs encoding the closely related but oppos-
ingly acting Rev-erb and (RVR) orphan nuclear receptors
(Fig. 1, I and J), which are abundantly expressed in prolifer-
ating myogenic cells but are repressed during myogenic differ-
entiation. This is in concordance with previous observations
(50, 51).
Ectopic RORE Expression Represses Endogenous Levels of
ROR and - and Attenuates ROR-dependent Gene Expres-
sion—To understand the biological role of ROR in skeletal
muscle lipid homeostasis and to identify the metabolic target(s)
of this orphan receptor in muscle cells, we proceeded to exam-
ine the effect of attenuating ROR function in C2C12 cells.
In order to perturb ROR function and to disrupt ROR-medi-
ated gene expression, we utilized the RORDE plasmid. This
construct encodes amino acids 1–235 but lacks the entire E
region and part of the hinge/D region of ROR. This was chosen
because McBroom et al. (30) reported that deletion of this
region preserved DNA binding but destroyed trans-activation
and operated in a dominant negative manner. Furthermore,
the “staggerer” phenotype in mice is because of a frameshift
mutation in ROR (29), which produces a similar nonfunc-
tional C-terminal domain. Finally, we noted that GAL4 hybrid
analysis indicated that the ROR activation domain was lo-
cated downstream of amino acid position 235 (Fig. 2A). More-
over, in concordance with this observation, we demonstrated
that RORDE (ROR1-(1–235)) ablated the ROR-mediated
trans-activation of the synthetic (ROREx5) and native (mPCP-
2  4) ROR-dependent response elements linked to the basal
tk-LUC reporter (Fig. 2, B and C). Also shown is the opposingly
acting RVR/rev-erb  orphan that does not trans-activate the
ROREs. Moreover, the RORDE repressed the ROR-mediated
trans-activation of the synthetic heterologous RORE-tk-LUC
reporter in a dose-dependent manner, similar to the orphan
receptor RVR (Fig. 2, D and E). This demonstrated that this
construct, as expected from studies on the staggerer form of
ROR and other forms of ROR that lack the entire E region and
parts of the hinge, attenuated ROR-dependent gene expression.
We stably (and independently) cotransfected two populations
of C2C12 cells with RORDE and pCMV-NEO expression vec-
tors. Stable RORDE transfectants were isolated as two inde-
pendent polyclonal pools of G418-resistant colonies (composed
of 20 individually resistant colonies). The C2:RORDE cells
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were transfected with pSG5-RORDE (i.e. amino acids 1–235).
The two polyclonal pools of C2-ROR1-(1–235) cells abun-
dantly expressed the ectopic/exogenous human transcript rel-
ative to GAPDH and 18 S rRNA controls. This was demon-
strated rigorously by quantitative real time PCR with primers
that specifically detect the human-specific transcript expressed
from the expression vector (Fig. 3, A and B) and Northern
analysis (Fig. 3C). Furthermore, the total pool size of ROR
mRNA increased 2–3-fold when measured by real time PCR
with primers that detected both mouse and human transcripts
(Fig. 3D). Most interestingly, we observed by real time PCR
and Northern analysis that the endogenous levels of the mouse
ROR mRNA transcripts were reduced in both polyclonal pools
of the C2-ROR1-(1–235) cells (Fig. 3, E and F) relative to the
wild type levels. The down-regulation of the endogenous ROR
transcripts is not surprising. During myogenesis mRNA pool
sizes in muscle tissue are under strict control (31), and mech-
anisms exist that sense total output from exogenous and en-
dogenous genes (32). Furthermore, exogenous expression of a
number of different contractile protein transgenes in the mouse
(e.g. myosin light chain 2 and troponin I fast, skeletal, and
cardiac actin) results in the decline in the expression of the
FIG. 1. ROR mRNA expression in skeletal muscle cells. A, schematic illustration of the cell culture model. Proliferating myoblasts are
cultured in DMEM supplemented with 10% serum supreme. Myoblasts were differentiated into post-mitotic multinucleated myotubes by 1–5 days
of serum withdrawal (i.e. cultured in DMEM supplemented with 2% horse serum). B–J, Q-RT-PCR analysis of ROR and - mRNA expression
during skeletal myogenesis. Total RNA was extracted from C2C12 proliferating myoblasts (PMB), confluent myoblasts (CMB), and myotube (MT)
after 2 days of serum withdrawal (MT2) and myotubes after 5 days of serum withdrawal (MT5), and 7 g of each sample was reverse-transcribed
to cDNA. Subsequently, 0.6% of the cDNA was analyzed by Q-RT-PCR (see “Materials and Methods”). B, Q-RT-PCR analysis of mROR levels. C,
Northern analysis of ROR mRNA levels as reported previously (19). Q-RT-PCR analyses of mROR mRNA levels (D); mRNA levels (MyoG) (E);
-actin mRNA levels (F); troponin I slow/type 1 (TNNI1) mRNA levels (G); troponin I fast/type II (TNNI2) mRNA levels (H); RVR mRNA levels
(I); and Rev-erb mRNA levels (J). (Primer sequences and experimental conditions for Q-RT-PCR are described under “Materials and Methods.”)
Levels of 18 S were measured in all samples, and the results were normalized and presented as number of target transcripts per 18 S transcript.
For example -actin is equivalently expressed to 18 S.
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corresponding endogenous gene (32–36). Finally, we observed
that ectopic expression of the RORDE in muscle C2 cells
completely ablated ROR mRNA expression (Fig. 3G).
In conclusion, the cell lines ectopically expressed a dominant
negative ROR expression vector that compromises ROR func-
tion and ROR-dependent gene expression. Moreover, ROR
mRNA expression is attenuated, and ROR mRNA expression
is ablated.
ROR Regulates Lipid Homeostasis; Dominant Negative ROR
Activity Represses the Expression of Genes Involved in Lipid
Absorption, Utilization, and Efflux—We investigated the ex-
pression of the genes involved in skeletal muscle lipid and
carbohydrate metabolism (see Table I) in the wild type and the
RORDE-expressing C2C12 cells. This in vitro cell culture
system has been used to investigate the regulation of choles-
terol homeostasis and lipid metabolism by LXR agonists (22).
Muscat et al. (22) demonstrated that the selective and synthetic
liver X receptor (LXR) agonist, T0901317, induced similar ef-
fects on mRNAs encoding the ATP-binding cassette A1/G1
(ABCA1/G1), apolipoprotein E (apoE), stearoyl-CoA desatu-
rase-1 (SCD-1), sterol regulatory element binding protein-
1c (SREBP-1c), etc. in differentiated C2C12 myotubes and
M. musculus quadriceps skeletal muscle tissue. Moreover,
treatment of these cells with PPAR and - agonists and an
FIG. 2. ROR-(1–235)/RORDE attenuates ROR-dependent gene expression. A, diagrammatic representation of ROR and the Gal4-ROR
chimeric constructs. Each well of a 6-well plate of COS-1 cells (60% confluence) was cotransfected with 1.0 g of the Gal4-ROR chimera and 3.0
g of the GAL reporter G5EIb-CAT by the liposome-mediated transfection procedure as described under “Materials and Methods.” Briefly, the
DNA/liposome mix was added to the cells in 3 ml of DMEM supplemented with 5% charcoal-stripped fetal calf serum. 16–24 h later, the culture
medium was changed, and the cells were subsequently harvested for the assay of CAT enzyme activity 24–48 h after the transfection period. Fold
activation is expressed relative to CAT activity obtained after cotransfection of the Gal4 DNA-binding domain alone, arbitrarily set at 1. The mean
fold activation values and S.D. (bars) were derived from a minimum of two independent triplicate experiments. B, each well of a 24-well plate of
COS-1 cells (60% confluence) was cotransfected with either 0.33 g of the synthetic reporter, ROREx5-tk-LUC (the RORE sequences are
described under “Materials and Methods”). Additionally, either 0.32 g of pSG5, 0.16 g each of pSG5-RORa and pSG5, 0.16 g each of
pSG5-RORa1 and pSG5-RORDE, or 0.16 g each of pSG5-RORa and pSG5-RVR (i.e. a total of 0.65 g of DNA per well) used the liposome-
mediated transfection procedure as described in A. Fold activation is expressed relative to LUC activity obtained after cotransfection of the
reporter, and pSG5 vector only was arbitrarily set at 1. The mean fold activation values and S.D. (bars) were derived from a minimum of two
independent experiments composed of six replicates. C, identical to B, except the native reporter, mPCP-2x4-tk-LUC, has been utilized. D and E,
COS-1 cells were transiently transfected as above with 0.32 g of the synthetic reporter, ROREx5-tk-LUC. The control transfection (C), arbitrarily
set to 1, also contained 0.32 g of the pSG5 vector alone. All the other transfections contained 0.16 g of pSG5-RORa1 per well of a 24-well plate.
Additionally, the three denoted transfections were cotransfected with increasing amounts (0.04, 0.08, and 0.16 g) of pSG5-RORDE (D) and
pSG5-RVR (E), respectively. The vector pSG5 was used to standardize the quantity of DNA to a total of 0.65 g of DNA per well. Fold activation
is expressed relative to luciferase activity obtained after cotransfection of the reporter with the pSG5 vector alone, arbitrarily set at 1. The mean
luciferase fold activation values and S.D. (bars) were derived from a minimum of 2–3 independent experiments composed of six replicates.
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analysis of critical genes (12) involved in lipid and carbohy-
drate metabolism revealed similar responses to quadriceps tis-
sue from agonist-treated C57BL/6J mice (21–23). The physio-
logical validation of the cell culture model with respect to lipid
homeostasis in the mouse corroborates the utility of this model
system. This evidence, coupled to the flexibility and utility of
cell culture in terms of manipulation, RNA extraction, and
target validation provides an ideal platform to identify the
ROR-dependent regulation of genes involved in metabolism.
In addition and more importantly, we have demonstrated this
cell line expresses ROR and - receptors and that the stable
cell line produced by ectopic RORE overexpression has com-
promised endogenous ROR/ expression and function.
We isolated total RNA from the native (wild type) and
RORDE-differentiated myotubes, and we analyzed the ex-
pression levels of several myogenic mRNAs by quantitative
real time PCR. We demonstrated as reported previously (19)
that these cells retain the potential to differentiate (although
FIG. 3. Q-RT-PCR analyses of the RORDE stably transfected C2C12 cell line. Q-RT-PCR analysis of endogenous and exogenous/ectopic
ROR mRNA expression in two independent populations of native/wild type (wt) differentiated mouse C2C12 cells and two independent polyclonal
pools of the C2C12 cells were stably transfected with the dominant negative human RORa1DE expression vector after 5 days of serum
withdrawal. These cells were denoted as wild type C2s and C2:RORDE, respectively. A, Q-RT-PCR analysis of the dominant negative human
ROR (hROR) mRNA expression in the two independent populations of wild type mouse C2C12 cells, and the two independently transfected
polyclonal pools of the C2:RORDE cells relative to the GAPDH control. B, Q-RT-PCR analysis of hROR mRNA expression relative to the 18 S
rRNA control. C, Northern analysis of the dominant negative human ROR mRNA as reported previously (19). Total RNA from proliferating
myoblasts (PMB) and myotubes after 2 days of serum withdrawal (MT2) was isolated from wild type and stably transfected cells. Subsequently,
RNA was Northern-blotted and hybridized with a 32P-labeled human ROR probe and an oligo that recognizes the 18 S rRNA. D, Q-RT-PCR analysis
of total mouse human ROR mRNA levels (mhROR) using primers that recognize the mouse and human RORs. E, Q-RT-PCR analysis of mouse
ROR (mROR) that measure the levels of the endogenous ROR mRNA levels. F, Northern analysis of the endogenous mouse ROR as reported
previously. G, Q-RT-PCR analysis of mouse ROR that measure the levels of the endogenous ROR mRNA levels. Specific primer sequences and
PCR conditions are described under “Materials and Methods.”
TABLE I
Key target genes in this study
ABCA1 and ABCG8 ATP-binding cassette. Transporters that transfer cholesterol to the HDL acceptors, i.e. reverse cholesterol efflux
ACS4 Acyl-CoA synthetase-4. Enhances the uptake of fatty acids by catalyzing their activation to acyl-CoA esters for
subsequent use in catabolic fatty acid oxidation pathways
ADRP/adipophilin Adipocyte differentiation-related protein. Involved in lipid storage
AdipoR1 and -R2 Adiponectin receptors 1 and 2. Cell surface membrane receptors for adiponectin that regulate glucose uptake and
fatty acid oxidation (54)
ApoE Apolipoprotein E. Facilitates cholesterol and lipid efflux
CAV-3 Caveolin-3. Muscle-specific caveolin involved in membrane protein anchoring, caveolae, t-tubule formation, and
lipid trafficking
CPT-1 Carnitine palmitoyltransferase-1. Transfers the long chain fatty acyl group from coenzyme A to carnitine, the
initial reaction of mitochondrial import of long chain fatty acids, and their subsequent oxidation
FAS Fatty-acid synthase. Involved in de novo fatty acid production
FAT/fatty acid translocase
and FABP3
Fatty acid translocase and fatty acid binding protein. Facilitates uptake of long chain fatty acids and low density
lipoproteins
GLUT4 and -5 Glucose transporters. GLUT4 facilitates glucose uptake in response to insulin stimulation. GLUT5 catalyzes
uptake of fructose
Glycogenin/GYG1 Initiates the synthesis of glycogen, the principal storage form of glucose in skeletal muscle
LPL Lipoprotein lipase. Hydrolysis of lipoprotein triglycerides into free fatty acids and responsible for the uptake of
free fatty acids
PDK-2 and -4 Pyruvate dehydroxygenase kinases. Inhibit the pyruvate dehydroxygenase complex, thereby controlling glucose
oxidation and maintaining pyruvate for gluconeogenesis
SCD-1 and -2 Stearoyl-CoA desaturase-1 and -2. Enzymes associated with adiposity, i.e. storage and esterification of cholesterol
and responsible for the cis saturation of stearoyl and palmitoyl-CoA converting them to oleate and palmitoleate,
which are the monounsaturated fatty acids of triglycerides
SREBP-1c Sterol regulatory element binding protein-1c, the hierarchical transcriptional activator of lipogenesis
UCP-1, -2 and -3 Uncoupling proteins. Mitochondrial proteins that uncouple metabolic fuel oxidation from ATP synthesis,
regulating energy expenditure
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the initial rate is impaired slightly), exit the cell cycle, and
express all genes associated with contraction and lipid metab-
olism (data not shown). This suggests that ectopic RORDE
expression does not significantly affect proliferation, cell cycle
withdrawal, differentiation, and/or phenotypic acquisition of
these skeletal muscle cells.
Subsequently, we utilized quantitative real time PCR to
investigate the expression pattern of genes involved in fatty
acid and lipid absorption (fatty acid translocase (FAT/CD36),
fatty acid binding proteins 3 and 4 (FABP3 and -4), triglyceride
hydrolysis (lipoprotein lipase (LPL)), and fatty acid oxidation
(muscle-type carnitine palmitoyltransferase-1 (M-CPT-1), acyl-
CoA synthetase-4 (ACS-4), adiponectin receptors 1 and 2), glu-
cose/fructose absorption, and utilization (glucose transporters
4, and 5 (GLUT4 and -5)), in total RNA isolated from C2C12
and C2:RORE myotubes differentiated for 5 days.
In the context of lipid and fatty acid uptake, we observed
significant repression of the mRNAs encoding fatty acid trans-
locase (FAT/CD36), and fatty acid binding protein 3 (FABP3),
with only minor changes observed for fatty acid binding protein
4 (FABP4) in the RORE-expressing cell line, respectively (Fig.
4, A–C).
The transcripts encoding lipoprotein lipase, M-CPT-1, and
acyl-CoA synthetase-4 (ACS-4), which are involved in triglyc-
eride-hydrolysis, fatty acid-oxidation, and preferential fuel uti-
lization, were significantly repressed 5–7-fold in the RNA
isolated from the cell line overexpressing RORE (Fig. 4, F–H).
The significance of the repression is highlighted by the obser-
vation that expression of PPAR- coactivator-1 (PGC-1) mRNA
(Fig. 4K), myogenin (myoG) mRNA (Fig. 4W) (which encodes
the hierarchical bHLH regulator), and -actin mRNA(Fig. 4X)
was reduced 2-fold. Moreover, the changes observed are not
due to the effects of RORE expression on differentiation. Over
a 5-day period the cell line retained the potential to differenti-
ate as measured by the induction and activation of myoG (Fig.
4Y), troponin I slow ((TNNI1) Fig. 4A(ii)), troponin I fast
((TNNI2) (Fig. 4B(ii)), and repression of -actin (Fig. 4Z)
mRNA expression, respectively, after serum withdrawal.
Most interestingly, the adiponectin receptors 1 and 2 that
mediate increased AMP kinase levels, as well as fatty acid
oxidation and glucose uptake by adiponectin, were significantly
repressed (Fig. 4, I and J). This correlates with the significant
repression of glucose transporter 4 (GLUT4) mRNA expression
but not glucose transporter 5 (GLUT5) mRNA (Fig. 4, D and E).
However, we note that these cell lines express very low levels of
the glucose transporters 4/5 (GLUT4/5) transcripts.
Subsequently, we examined the expression of genes involved
in fatty acid and lipid absorption, lipid and cholesterol efflux
(ATP binding cassette A1 and G1 (ABCA1/G1) and apoE), lipid
storage, homeostasis (adipophilin/adipocyte differentiation-
related protein (ADRP) and caveolin-3 (Cav-3)), lipogene-
sis ((SREBP-1c), fatty-acid synthase (FAS), stearoyl-CoA de-
saturase-1 and -2 (SCD-1 and -2; Fig. 4B and Fig. 4E)), and
energy expenditure (uncoupling protein-1, -2, and -3 (UCP-1,
-2, and -3)).
In the two polyclonal populations of cells expressing RORE
dramatic repression, we observed dramatic reduction in the
expression of mRNAs encoding ATP-binding cassette A1
(ABCA1) and apoE but minor/subtle changes in ATP-binding
cassette A8/G1 (ABCA1/G1) levels (Fig. 4, N–P). Most interest-
ingly, we observed significantly decreased levels of the mRNA
encoding caveolin-3 (Cav-3) (Fig. 4Q), the major structural
protein of caveolae in skeletal muscle, which has been impli-
cated in cholesterol homeostasis. Similarly, we observed re-
duced expression of ADRP mRNA, a protein involved in lipid
droplet formation. (Fig. 4R). The mRNAs encoding the hierar-
chical regulator of lipogenesis, SREBP-1c (Fig. 4S), and the
lipogenic genes (SCD-1 and -2 and FAS) (Fig. 4, T–V) were all
notably reduced in the RORDE-expressing cell lines. Further-
more, the mRNAs encoding UCP-2 and -3, which encode un-
coupling proteins involved in energy uncoupling/expenditure
and preferential lipid utilization, were significantly repressed
by the expression of ectopic dominant negative ROR (Fig. 4, L
and M).
Finally, the expression of the closely related but opposingly
acting orphan receptors, Rev-erb and Rev-erb/RVR, was fur-
ther repressed by RORE expression (Fig. 5, A and B). This
was expected as ROR has been demonstrated to regulate the
Rev-erb gene.
PGC-1 Efficiently Coactivates the Synthetic and Native
RORE Heterologous Reporter Genes—We then investigated the
ability of ROR to activate the synthetic and wild type ROR-de-
pendent reporter in COS-1 cells and the ability of the cofactors
p300, SRC-2/GRIP-1, and PGC-1 to coactivate ROR-dependent
activation of gene expression. We utilized the synthetic RO-
REx5-tk-LUC reporter that contains five copies of a consensus
binding site (24) and the native mPCP-2x4-tk-LUC containing
four copies of the mouse Purkinje cell protein-2 RORE motif
(25) cloned upstream of the heterologous herpes simplex virus
thymidine kinase (tk) promoter linked to the luciferase re-
porter gene, respectively. As shown, ROR expression effi-
ciently activated the expression of the synthetic (Fig. 6A) and
native RORE (Fig. 6B)-containing reporters in COS-1 cells
several hundredfold. In contrast, ROR relatively insignifi-
cantly (i.e. 
10-fold) regulated the basal tk-LUC-backbone,
lacking the RORE (Fig. 6C).
Furthermore, we observed that ROR-dependent activation
of the synthetic RORE was significantly enhanced by the coac-
tivator, PGC-1, relative to p300 and SRC-2/GRIP-1. Similarly,
ROR-dependent activation of the native RORE was most effi-
ciently coactivated by PGC-1, relative to p300 and SRC-2/
GRIP-1. In summary, we demonstrate that PGC-1 expression
Fig. 4. Expression profiling of mRNAs involved in metabolism by Q-RT-PCR analyses of the wild type native C2C12 cells and the
C2:RORDE stably transfected cells. Q-RT-PCR analysis of endogenous mRNA expression encoding enzymes/proteins involved in lipid
homeostasis, energy expenditure, etc. (described in Table I) in two independent populations of native/wild type (wt) differentiated mouse C2C12
cells, and two independent polyclonal pools of the C2C12 cells stably transfected with the dominant negative human RORa1DE expression vector,
after 5 days of serum withdrawal are shown. These cells were denoted as wt C2s, and C2:RORDE, respectively. Levels of 18 S were measured
in all samples; the results were normalized and presented as the number of target transcripts per 18 S transcript. For example, -actin is
equivalently expressed to 18 S. A–C, Q-RT-PCR analysis of mRNA expression encoding proteins/enzymes involved in lipid absorption that are
completely described in Table I. A, fatty acid translocase (CD36/FAT); B, fatty acid binding protein 3 (FABP3); and C, FABP4. D and E, Q-RT-PCR
analysis of mRNA expression encoding proteins/enzymes involved in glucose uptake that are completely described in Table I. D, GLUT4; E, GLUT5.
F–K, Q-RT-PCR analysis of mRNA expression encoding proteins/enzymes involved in lipid catabolism that are completely described in Table I. F,
LPL; G, CPT-1; H, ACS-4; I and J, adiponectin receptors 1 and 2 (adipoR1 and R2); K, PGC-1. L and M, Q-RT-PCR analysis of mRNA expression
encoding proteins/enzymes involved in energy expenditure that are completely described in Table I. L, UCP-2; M, UCP-3. N–R, Q-RT-PCR analysis
of mRNA expression encoding proteins/enzymes involved in lipid efflux and storage that are completely described in Table I. N, ABCA1; O,
ABCA8/G1; P, apoE; Q, Cav-3; R, ADRP. S–V, Q-RT-PCR analysis of mRNA expression encoding proteins/enzymes involved in lipogenesis that are
completely described in Table I. S, SREBP-1c; T, SCD-1; U, SCD-2; V, FAS. W–Z, Aii, and Bii, Q-RT-PCR analysis of mRNA expression encoding
proteins associated with differentiation of the C2:RORDE cell line, i.e. MyoG, -actin, TNNI1, and TNNI2. W, MyoG; X, -actin; Y, MyoG; Z,
-actin; Aii, TNNI1; Bii, TNNI2.
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selectively coactivates ROR-mediated activation of the heter-
ologous synthetic and native RORE-tk-LUC reporters.
M-CPT-1 and Cav-3 Genes Are Primary Targets of ROR in
Skeletal Muscle—We further explored the molecular basis of
ROR-mediated gene activation in skeletal muscle cells by eval-
uating whether direct or indirect mechanisms mediated the
observed changes in mRNA levels in the RORDE cells. We
investigated the responsiveness of the promoters of selected
target genes to ROR coexpression in a cell-based reporter
assay.
We transiently transfected COS-1 cells with the regulatory
sequences of selected target genes, including ABCA1 (22),
CD36/FAT (37), LPL (38), M-CPT-1 (26), Cav-3, GLUT4, and
UCP-2 (39), cloned in front of the pGL2/3 basic luciferase back-
bone, and we examined the response after cotransfection of
ROR in the presence and absence of p300, SRC-2/GRIP-1, and
PGC-1.
Most interestingly, the M-CPT-1 promoter (and not several
other promoters including GLUT4), which contains 1025 bp
upstream of the start of translation, was efficiently activated
by ROR expression (Fig. 7A). Moreover, we observed that p300
and PGC-1 significantly enhanced the transactivation of the
M-CPT-1 (Fig. 7B). The transcriptional coactivators p300 and
PGC-1 are expressed in skeletal muscle and have been demon-
strated to potentiate myogenesis, mitochondrial biogenesis, ox-
idative metabolism, fiber type transitions (fast (type II) to slow
(type I)), and thermogenesis. Furthermore, we observed similar
ROR-dependent activation and cofactor preference with a
VP16-ROR chimera (Fig. 7C). Most interestingly, the
p-mCav3–2595-LUC promoter that encompasses 2595 bp im-
mediately upstream of the murine Cav-3 transcription start
site (that drives the expression of the muscle-specific caveolin-3
gene) was also efficiently activated by ROR expression
(Fig. 8A).
FIG. 5. Q-RT-PCR analyses of orphan nuclear receptor expres-
sion in the hRORDE stably transfected C2C12 cell line. Q-RT-
PCR analysis of endogenous mRNAs encoding the closely related
Rev-erb and RVR orphan nuclear receptors in two independent popu-
lations of native/wild type (wt) differentiated mouse C2C12 cells and
two independent polyclonal pools of the C2C12 cells stably transfected
with the dominant negative human RORDE expression vector, after 5
days of serum withdrawal, are shown. These cells were denoted as wt
C2s and C2:RORDE, respectively. Q-RT-PCR analyses of RVR mRNA
expression (A) and Rev-erb mRNA expression (B) in wt C2s and
C2:RORDE cells. Specific primer sequences and conditions for RVR
and Rev-erb Q-RT-PCR are described under “Materials and Methods.”
Levels of 18 S were measured in all samples, and the results are
presented as number of target transcripts per 18 S transcript. For
example -actin is equivalently expressed to 18 S. FIG. 6. PGC-1 acts as a transcriptional coactivator for ROR-
mediated activation of the heterologous synthetic and native
RORE reporter genes. A, each well of a 24-well plate of COS-1 cells
(60% confluence) was cotransfected with 0.33 g of the synthetic
reporter (i.e. the ROREx5-tk-LUC containing five copies of the TATAT-
CAAGGTCAT sequence), 0.33 g of either pSG5 or pSG5-ROR1, and
0.1 g of pcDNA expression vectors encoding p300, SRC-2/GRIP-1, and
PGC-1 (i.e. a total of 0.7 g of DNA per well) by using the liposome-
mediated transfection procedure as described previously. Fold activa-
tion is expressed relative to LUC activity obtained after cotransfection
of the reporter and vector only, arbitrarily set at 1. The mean fold
activation values and S.D. (bars) were derived from a minimum of two
independent experiments composed of six replicates. B, each well of a
24-well plate of COS-1 cells (60% confluence) was cotransfected with
0.33 g of the native reporter (i.e. the mouse PCP-2x4-tk-LUC contains
four copies of the native sequence GTTATAGTAACTGGGTCAGGG-
GACT), 0.33 g of either pSG5 or pSG5-ROR1, and 0.1 g of pcDNA
expression vectors encoding p300, SRC-2/GRIP-1, and PGC-1.(i.e. a
total of 0.7 g DNA per well) using the liposome-mediated transfec-
tion procedure as described. C, each well of a 24-well plate of COS-1
cells (60% confluence) was cotransfected with 0.33 g of the tk-LUC
vector, 0.33 g of either pSG5 or pSG5-ROR1, and 0.1 g of pcDNA
expression vectors encoding p300, SRC-2/GRIP-1, and PGC-1 (i.e. a
total of 0.7 g of DNA per well) by using the liposome-mediated
transfection procedure as described previously and above.
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In an attempt to further elucidate which sequences were
necessary for the trans-activation of the mCav-3-LUC promoter
by ROR, we utilized a series of 5 unidirectional deletions in
the mCav-3 promoter. Several deletion constructs were
produced, namely p-mCav3–988-LUC, p-mCav3–654-LUC,
p-mCav3–477-LUC, and p-mCav3–279-LUC, which contained
988, 654, 477, and 279 nucleotides, respectively, of 5-flanking
sequences cloned upstream of the luciferase reporter in pGL2-
Basic. By transfecting the full-length and deleted promoters in
the absence/presence of the ROR expression vector in COS-1
cells, we could demonstrate that the sequences between nucle-
otide position 	2595 and 	988 were necessary for ROR-de-
pendent activation (Fig. 8A). Moreover, we observed that p300
and SRC-2/GRIP-1 significantly enhanced the transactivation
of the mCav-3 promoter. (Fig. 8B).
To define rigorously the molecular basis of direct ROR action,
we focused on one of the promoters that we defined as a pri-
mary ROR target gene. We selected and scanned the mouse
caveolin-3 promoter by the Mat inspector program to identify
putative AGGTCA nuclear receptor binding motifs. We ob-
served six putative ROR monomeric binding motifs m1–m6,
located between nucleotide positions 	2498/	2474, 2378/
	2357, 	1739/	1713, 	1720/	1690, 	1587/	1556, and
	1005/	984, respectively (Fig. 8C). These motifs to varying
degrees could be accommodated by the asymmetric (A/
T)6RGGTCA ROR recognition motif and were located in the
delimited region between nucleotide positions	2595 and	988
that were necessary for ROR-dependent activation.
Subsequently, we examined the ability of the motifs 1–6 to
interact with GST-ROR, and we observed that motifs 2 and
4–6 bound ROR with different efficiencies in an EMSA assay,
relative to our control ROR recognition motif, the mouse PCP-2
RORE (Fig. 8D). However, we observed that only the m2 and
m6 (and the synthetic RORE), but not the m1 and M3–M5
motifs) efficiently competed against the efficient GST-ROR-
mPCP-2 RORE interaction (Fig. 8E). This suggested that ei-
ther motif 2 or 6 mediated ROR activation of the mouse caveo-
lin-3 gene. Hence, we independently mutated the GG
nucleotide in the nuclear receptor half-sites to TT in the m2
and m6 putative ROREs within the native caveolin-3 promoter,
and we examined the ability of ROR (in the presence of the
cofactor p300) to trans-activate the caveolin-3 promoter. We
observed that the mutation of motif 6 in the mouse caveolin-3
promoter compromised the ability of ROR to trans-activate the
promoter (Fig. 8F). This was also consistent with the analysis
of several additional 5 unidirectional deletion mutants of the
caveolin-3 promoter between 	2595 and 	984 that were ex-
amined (data not shown).
In summary, these transfections demonstrated that ROR
directly regulates the CPT-1 and Cav-3 genes that potentially
encode proteins involved in -oxidation and cholesterol home-
ostasis. Moreover, we defined the specific sequences in a mus-
cle-specific gene (i.e. caveolin-3) that mediated the direct reg-
ulation of expression by ROR. This suggests that ROR has a
central role in the regulation of lipid homeostasis.
DISCUSSION
Genetic, molecular, and biochemical studies have demon-
strated that NR1F1 (ROR)-deficient mice develop severe ath-
erosclerosis, low HDL-C, hypo--lipoproteinemia, muscular at-
rophy, and heightened inflammatory responses. Moreover,
NR1F1 regulates the expression of apolipoprotein CIII, a com-
ponent of HDL and very low density lipoprotein that plays a
role in regulation of triglyceride levels and lipoprotein lipase
activity. Furthermore, ROR potentiates the acquisition of the
skeletal muscle phenotype.
The expression of ROR in skeletal muscle, a peripheral lean
tissue that has a significant role in energy consumption, glu-
cose disposal, and free fatty acid uptake prompted us to inves-
tigate the regulatory role of ROR in skeletal muscle cells, with
respect to gene expression involved in metabolism. Our study
demonstrates that ROR regulates the expression of genes
FIG. 7. The M-CPT-1 promoter is directly activated by ROR
and coactivated by p300 and PGC-1. A, each well of a 24-well plate
of COS-1 cells (60% confluence) was cotransfected with either 0.33 g
of pGL2-basic, pGL2-MCPT1(	1025/	12), or pGL2-GLUT4, and 0.33 g of
either pSG5 or pSG5-ROR1 (i.e. a total of 0.66 g of DNA per well)
by using the liposome-mediated transfection procedure as described
previously and above (Fig. 6A). B, each well of a 24-well plate of COS-1
cells (60% confluence) was cotransfected with 0.33 g of pGL2-
MCPT1(	1025/	12), 0.33 g of either pSG5 or pSG5-ROR1, and 0.1 g of
pcDNA expression vectors encoding p300, SRC-2/GRIP-1, and PGC-1
(i.e. a total of 0.7 g of DNA per well) using the liposome-mediated
transfection procedure as described. C, each well of a 24-well plate of
COS-1 cells (60% confluence) was cotransfected with 0.33 g of pGL2-
MCPT1(	1025/	12), 0.33 g of either VP16 vector alone or the VP16-
ROR1 chimera, and 0.1 g of pcDNA expression vectors encoding
p300, SRC-2/GRIP-1, and PGC-1.(i.e. a total of 0.66 g of DNA per
well) by using the liposome-mediated transfection procedure as
described.
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FIG. 8. The caveolin-3 promoter is directly activated by ROR and coactivated by p300 and SRC-2. A, each well of a 24-well plate of
COS-1 cells (60% confluence) was cotransfected with either 0.33 g of pGL3-basic and a series of mouse pGL3-mCav3 promoter deletions
	2595/35 (2595), 	988/35 (988), 	654/35 (654), 	477/35 (477), 	279/35 (279), and 0.33 g of either pSG5 or pSG5-ROR1 (i.e. a total of
0.66 g of DNA per well) using the liposome-mediated transfection procedure as described above. B, each well of a 24-well plate of COS-1 cells
(60% confluence) was cotransfected with 0.33 g of pGL3-mCav3-LUC (	2595/35), 0.33 g of either pSG5 or pSG5-ROR1, and 0.1 g of pcDNA
expression vectors encoding p300, SRC-2/GRIP-1, and PGC-1.(i.e. a total of 0.7 g of DNA per well) by using the liposome-mediated transfection
procedure as described above. C, sequence of putative RORE motifs (in boldface) identified in the mouse caveolin-3 promoter. TT below the line
denotes mutagenesis of the bases above from GG to TT by QuickChange site-directed mutagenesis referred to in F. D, EMSA analysis examining the
differential interaction of the six putative RORE motifs in the caveolin-3 promoter (denoted as Cav-3 motifs (m) 1–6) with GST-ROR1. 300 cps of
PAGE-purified, 32P-end radiolabeled Cav-3 m1–6 were incubated with 0.4 g of GST-ROR1 protein before PAGE separation. The mPCP-2
radiolabeled probe was used as a positive control (see “Materials and Methods”). E, EMSA analysis examining the ability of the six putative m1–6
ROREs (at 10- and 30-fold excess) to efficiently compete the mPCP-2ROR complex. 32P-Radiolabeled mouse PCP-2 RORE probe was coincubated with
0.4 g of GST-ROR1 protein, and 100 and 300 ng of unlabeled putative Cav-3 m1–6 ROREs before PAGE separation. Cold mPCP-2 and synthetic
ROREs were used as the control competitors (see “Materials and Methods”). F, each well of a 24-well plate of COS-1 cells (60% confluence) was
cotransfected with 0.4 g of pGL3-mCav3-LUC (	2595/35) or pGL3-mCav3-LUC (	2595/35) carrying the GG to TT mutations in motifs 2 and 6 (see
C) in the presence 0.1 g of pcDNA or pcDNA-p300 and 0.16 g of pSG5 or pSG5-ROR1 as described under “Materials and Methods.”
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involved in lipid absorption, -oxidation, cholesterol efflux, and
energy expenditure in skeletal muscle cells. The observed
changes in gene expression in skeletal muscle are consistent
with the phenotype in this animal model.
The natural ROR mouse mutant, called staggerer (sg/sg), is
susceptible to high fat diet-induced atherosclerosis, with ath-
erosclerotic lesions in the aorta and the large and small coro-
nary arteries. In the context of this investigation, the staggerer
mice exhibit an aberrant blood lipid profile with lower circu-
lating plasma levels of HDL-C (associated with decreased
plasma apoA-I and apoA-II), reduced apoCIII, and plasma trig-
lycerides. Decreases in specific lipoprotein compartments,
namely apoAI, the major constituent of HDL, and apoAII, leads
to a pronounced hypo--lipoproteinemia (16). Accordingly, it
has been shown that ROR regulates the expression of apoAI
and apoCIII in cell culture (16, 17). Further studies in staggerer
mice correlate atherogenic susceptibility in this animal model
to a complex phenotype that includes aberrant vascular phys-
iology, lipid profiles, and inflammatory responses. However,
the contribution of skeletal muscle (atrophied in the ROR
sg/sg mice) and other putative target tissues to the staggerer
phenotype has not been resolved. Finally, ROR target genes
and the mechanism of action in this metabolically demanding
major mass lean tissue remained unclear.
The study by Mamontova et al. (40) demonstrated the ROR
sg/sg mice have lowered plasma HDL cholesterol. We demon-
strate that the muscle cells with attenuated ROR expression
and function display decreased ABCA1 mRNA expression. Fur-
thermore, we demonstrated that muscle-specific caveolin-3
mRNA expression is compromised in the cell line expressing
RORDE. In addition, we demonstrated that the caveolin-3
gene is a direct ROR target in muscle cells. Whereas caveo-
lin-3 has not been directly linked to lipid regulation, studies of
the non-muscle caveolin family member, caveolin-1, have sug-
gested a role for caveolins in cholesterol transport to extracel-
lular cholesterol acceptors such as HDL; increased caveolin-1
expression increases cholesterol efflux to extracellular accep-
tors. Furthermore, apoA-I and cholesterol acceptor availability
regulates caveolin-1 expression (41, 42). Nonstriated muscle
caveolins have also been linked to other aspects of lipid regu-
lation; caveolin-1 and -2 associate with lipid droplets in a fatty
acid-regulated fashion in cultured cells and in vivo (43). More-
over, caveolin-1 null mice are resistant to diet-induced obesity
(44) and show defective lipid droplet formation in a model
system (56). Recent studies (45) showed that caveolin-1 expres-
sion increases, and caveolin-2 expression decreases, in white
adipose tissue from rodents on a high fat diet. The studies
presented here linking ROR to the regulation of caveolin-3
and ADRP mRNA expression raises the intriguing possibility
that, like the non-muscle caveolins, caveolin-3 may play a role
in lipid regulation. This is consistent with studies showing that
a caveolin-3 mutant associates with lipid droplets and can
perturb the cellular balance of neutral lipids and free choles-
terol in cultured cells (43, 46).
We further observed in the cell line expressing ectopic dom-
inant negative ROR that expression of genes involved in lipid
absorption, lipid catabolism, lipogenesis, and energy expendi-
ture was significantly repressed. This provides further evi-
dence that ROR is a critical regulator of lipid homeostasis.
Moreover, the repression of SREBP-1c expression and its tar-
get genes (for example, FAS, SCD-1, and -2) in the muscle cell
line expressing the truncated ROR, similar in size and func-
tion to the form in the staggerer mouse, is consistent with the
reduced plasma triglycerides observed in this animal model. In
addition the staggerer mouse has lower apoCIII expression in
the liver, which affects lipoprotein metabolism.
The neural degeneration and motor and coordination (i.e.
spatial memory) abnormalities in staggerer mice are consistent
with the aberrant lipid metabolism observed. Defects in -
oxidation and lipid turnover are associated with neurologic
disease (47).
We demonstrate that ROR has a significant role in the
regulation of the mRNAs encoding the uncoupling proteins
(UCP-2 and -3, mitochondrial proton carriers) that control met-
abolic efficiency, energy expenditure, and thermogenesis by
uncoupling an oxidation/respiration-induced proton gradient
from ATP synthesis. The repression of UCP mRNA expression
correlates and is in concordance with the decreased mRNA
expression of genes involved in absorption and utilization of
lipids and fatty acids. For example, reduced lipoprotein lipase
activity in skeletal muscle results in decreased UCP-3 mRNA
expression, consistent with the hypothesis that it regulates the
flux of lipid substrates across the mitochondria. Moreover,
inhibition of fatty acid oxidation leads to reduced UCP-2 and -3
mRNA expression in slow twitch oxidative muscle fibers. stag-
gerer mice are lean despite their hyperphagia (like Cav-1 mice).
The lean phenotype may correlate with the decreased levels of
SCD-1 and -2 mRNA observed, although increased brown adi-
pose tissue activity may account for this phenotype.
In addition, we demonstrate that M-CPT-1, an established
target for PPAR in cardiac muscle (26, 48, 49) and PPAR/ in
skeletal muscle cells, is also directly regulated by ROR and
coactivated by p300 and PGC-1. Moreover, it suggests cross-
talk may occur between PPAR and ROR signaling in a tissue-
specific manner.
The fact that ROR is involved in all of these processes
highlights the crucial role of ROR in lipid homeostasis and
identifies ROR as a promising therapeutic target in the treat-
ment of dyslipidemia. Skeletal muscle is rapidly emerging as a
critical target tissue in the battle against obesity, type II dia-
betes, dyslipidemia, syndrome X, and atherosclerosis. For ex-
ample, NRs in skeletal muscle, such as LXR, PPAR, -/, and
-, have been shown to be involved in enhancing the insulin-
stimulated glucose disposal rate, decreasing triglycerides, and
increasing lipid catabolism, cholesterol efflux, and plasma
HDL-C levels (21–23). Hence, orphan NRs (for example ROR)
that regulate lipid and carbohydrate metabolism, energy ex-
penditure, and thermogenesis in skeletal muscle have enor-
mous pharmacological utility for the treatment of dyslipidemia
and syndrome X. In conclusion, we suggest that ROR in skel-
etal muscle cells programs a cascade of gene expression de-
signed to regulate lipid homeostasis. We hypothesize that
ROR is a critical regulator of lipid and energy homeostasis in
this major mass of lean tissue. Moreover, we suggest that the
atherogenic and dyslipidemic phenotype of the staggerer mouse
is related to aberrant ROR function in skeletal muscle. Fi-
nally, we surmise that ROR agonists may have therapeutic
utility in the treatment of hypercholesterolemia, atherosclero-
sis, and obesity.
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